Last Updated:
Current Pre-Prints
Cisneros LH, Toruner MD, Siddiqui Z, Maraone AV, Lin M, Xiao A, et al. Spatial Conformation of Pancreatic Cancer Is Associated with Disease Recurrence after Curative-Intent Total Neoadjuvant Therapy. BioRxiv [Preprint]. Nov 6, 2025. Available from: https://doi.org/10.1101/2025.11.03.686383v1
Cisneros LH, Toruner MD, Fernandez-Zapico ME, Maley CC, Carr RM. Tumor Landscape Analysis: An Ecologically Informed Framework to Understand Tumor Microenvironments. BioRxiv 646608 [Preprint]. April 22, 2025. Available from: https://doi.org/10.1101/2025.04.22.646608.
Peer-Reviewed Publications
Sherry AD, Bennett AK, Carr RM, Truty MJ, Jethwa KR. Contemporary advances, evidence, and considerations in preoperative therapy for pancreatic ductal adenocarcinoma. Semin Radiat Oncol. 2025;35(4):495-509.
Flores LF, Marks DL, Vera RE, Sigafoos AN, Tolosa EJ, et al. Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. JCI Insight. 2025;10(14):e187799.
Leiting JL, Alva-Ruiz R, Yonkus JA, Abdelrahman AM, Lynch IT, et al. Molecular KRAS ctDNA predicts metastases and survival in pancreatic cancer: A prospective cohort study. Ann Surg Oncol. 2025;32(6):4453-4463.
Chandra S, Halfdanarson TR, Carlson EE, Rabe KG, Mahipal A, et al. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Endocr Relat Cancer. 2025;32(4):e240142.
Gleeson FC, Dunleavy KA, Levy MJ, Carr RM, Hartgers ML, et al. Incidence and effect duration of immune checkpoint inhibitors-related pancreas adverse events. Pancreas. 2024;53(7):e627-e629.
Sigafoos AN, Tolosa EJ, Carr RM, Fernandez-Barrena MG, Almada LL, et al. KRAS promotes GLI2-dependent trranscription during pancreatic carcinogenesis. Cancer Res Commun. 2024;4(7):1677-1689.
Desai A, Xiao AH, Choi D, Toruner MD, Walden D, et al. Molecular characterization and therapeutic opportunities in KRAS wildtype pancreatic ductal adenocarcinoma. Cancers (Basel). 2024;16(10):1861.
Gatenby RA, Luddy KA, Teer JK, Berglund A, Freischel AR, et al. Lung adenocarcinomas without driver genes converge to common adaptive strategies through diverse genetic, epigenetic, and niche construction evolutionary pathways. Med Oncol. 2024;41(6):135.
Hogenson TL, Xie H, Phillips WJ, Toruner MD, Li JJ, et al. Culture media influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. JCI Insight. 2022;7(22):e158060.
Carr RM, Duma N, McCleary-Wheeler AL, et al. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of vismodegib and sirolimus combination. Pancreatology. 2020;20:1115-1122.
Tolosa EJ, Fernandez-Barrena MG, Iguchi E, McCleary-Wheeler AL, Carr RM, et al. GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression. Biochem J. 2020;477(17):3131-3145.
Carr RM, Romecin Duran PA, Tolosa EJ, et al. The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. J Biol Chem. 2020;295:2698-2712.
McCleary-Wheeler AL, Carr RM, Palmer SR, et al. Phase 1 trial of vismodegib and erlotinib combination in metastatic pancreatic cancer. Pancreatology. 2020;20:101-109.
Reviews
Raja Rul GL, Toruner MD, Gatenby RA, Carr RM. Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Pancreatology. 2022;22(6):730-740.
Editorials
Carr RM and Fernandez-Zapico ME. It takes a village to overcome KRAS dependence in pancreatic cancer. Cancer Discov. 2020;10:910-912.
Carr RM and Fernandez-Zapico ME. Toward personalized TGFB inhibition for pancreatic cancer. EMBO Mol Med. 2019;11:e11414.
Carr RM and Fernandez-Zapico ME. Pancreatic cancer microenvironment, to target or not to target? EMBO Mol Med. 2016;8:80-82.
Popular Press
Hull, Kathleen. “The Biggest Treasure Hunt You Can Imagine.” Mayo Clinic Magazine. August 23, 2024.